A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis

摘要

Background Cytosolic phospholipase A2 (cPLA2 alpha) is an enzyme suggested as a therapeutic target in inflammatory skin diseases. AVX001, a cPLA2 alpha inhibitor, was investigated in a randomized, double-blind, placebo-controlled, split-design, first-in-man study in patients with mild to moderate psoriasis.